News & Updates
Interested in learning more about Hyfe? Read about all of our news, announcements and updates here!
Interested in learning more about Hyfe? Read about all of our news, announcements and updates here!
Comprehensive Chronic Cough Report reveals $15B opportunity. 100M patients, zero FDA-approved drugs, positioning digital cough monitoring as essential pharma infrastructure.
Review including Hyfe research evaluates continuous digital cough monitoring as a practical way to address limitations of patient-reported cough data
Study results demonstrate digital Behavioral Cough Suppression Therapy reduced cough frequency by over 40% in patients with refractory and unexplained chronic cough.
Strategic partnership with KYORIN Pharmaceuticals aims to improve outcomes and expand treatment access to millions impacted by chronic cough globally.
Hyfe’s AI-powered cough monitoring is now available on Actigraph’s FDA-cleared LEAP wearable, enabling continuous, privacy-preserving cough tracking alongside key health biomarkers
Clinical Trial Results Demonstrate Alkaline Magnesium-Based Salt Aerosol Reduced Cough Frequency by up to 35% in Refractory Chronic Cough Patients with Cough Counts Measured Continuously by AI-Powered tech
Hyfe's cough tracker was used in study by University of Navarra, revealing significant variability in cough patterns. This breakthrough highlights potential for continuous, objective chronic cough monitoring.
CoughPro app introduces the world’s first digital Cough Management feature, offering AI-driven solutions for millions suffering from chronic cough.
Research demonstrates the accuracy of Hyfe’s automated cough monitoring process and is the first to observe differences in type and length of cough between men and women.
AI company transitions app to subscription model and adds exclusive new features for users in the UK, Canada, Europe and global users outside the U.S.
Hyfe's technology integrated into ActiGraph’s new FDA-cleared LEAP wearable device that will advance the use of remote patient monitoring in chronic cough clinical research.
Studies show remote patient monitoring technology better predicts cough exacerbations to ultimately improve quality of life and reduce healthcare costs for patients with chronic cough.
Hyfe is expanding into chronic cough treatment with the world's first digital therapeutic for cough, using a proprietary model that combines real time cough frequency with cough suppression therapy.
150 winners selected out of 13,000 private companies; Hyfe recognized for contributions in screening, monitoring and diagnostics technologies
Hyfe has entered into an agreement with Merck, to integrate its artificial intelligence-powered (AI) cough tracker technology into Merck’s consumer disease educational efforts.
Leader in acoustic epidemiology empowers health care providers, researchers, pharmaceutical companies, and patients with cough detection and classification platform
Scientists use Hyfe to confirm that continuous cough monitoring for Long COVID was more sensitive in evaluating cough variability and response to treatment compared to patient reported outcomes.
Dr. Peter Small, Hyfe Chief Medical Officer has delivered deliver an intervention to the G20 Meeting in Yogyakarta, Indonesia, on the role of digital innovation in addressing public health crises.
With apps and artificial intelligence, researchers want to use the cough to better diagnose asthma, Covid-19 and other respiratory illnesses
Accomplished physician, scientist, and product developer to lead Hyfe's efforts as it seeks to transform patient care through cough monitoring and diagnosis.
Studies show remote patient monitoring technology better predicts cough exacerbations to ultimately improve quality of life and reduce healthcare costs for patients with chronic cough.
Wilmington, Del., July 19, 2023 -- Hyfe, Inc., the global leader in AI-powered cough detection, tracking and classification, announces today the launch of its novel remote patient monitoring (RPM) program that is on track to provide an easy-to-use cough monitoring capability for virtual hospitals, remote care and telehealth programs across the U.S. The integration of Hyfe’s technology has the potential to enable providers to remotely monitor and treat patients with chronic cough and pulmonary diseases like COPD and asthma to improve quality of life, reduce healthcare costs and ease the burden on health systems.
Cough is the most common symptom for which patients seek medical care and an estimated 12 million adults in the United States – or about 5% of the adult population – have chronic cough. Until now, this symptom has not been quantified in any meaningful way, and has historically been extremely difficult to accurately measure and monitor. Hyfe’s AI-powered technology has been shown in clinical trials to accurately, passively and remotely detect, monitor, and report the number of times a person coughs. By giving RPM providers the ability to track longitudinal cough data, it will ultimately enable patients to better understand their cough and have more informed conversations with their providers.
Cough is one of the most common reasons patients seek health care and exacerbations are a leading cause of hospital and health clinic visits. Using RPM, a patient will receive advanced notice of an exacerbation up to 3.5 days in advance, according to a study published in the National Library of Medicine. Hyfe’s RPM capability can help track increases in cough leading up to an exacerbation event in order to provide treatment earlier and prevent hospitalizations. Better predicting these events using RPM would enhance quality of life and reduce costs for patients, while also improving the effectiveness and efficiency of health systems.
We’re excited to be on the forefront of building this capability for remote patient monitoring and believe that once FDA cleared, cough will be an inevitable biomarker to monitor in the future, just like temperature and blood pressure, and become essential for assessing health and medical conditions. We are already having conversations with clinics and technology companies who are eager to plan how to use RPM for cough tracking. We’re looking forward to bringing this technology to the pulmonary space and assisting patients and providers in making informed and thoughtful medical decisions.
Joe Brew
Co-founder and CEO of Hyfe
Hyfe’s cough monitoring technology is currently available as a wellness app and not yet FDA cleared as a medical device.
For more information, visit hyfe.
About Hyfe
Hyfe, Inc. is the global leader in AI-powered cough detection and classification that provides insight into cough patterns and correlations and is being widely used to help patients gain a better understanding of their cough and have more informed conversations with their providers.
With more than 700 million samples, Hyfe maintains the largest cough dataset in the world enabling the building of powerful models to track, manage and diagnose respiratory illnesses. Hyfe provides platforms and data for pharmaceutical companies, medical researchers, government agencies, health care providers and patients and has partnerships with leading academic institutions including Johns Hopkins University and the University of California at San Francisco. The company was founded in 2020 and is headquartered in Wilmington, Delaware. More information is available at hyfe.com, on social media @hyfeapp and LinkedIn at /hyfe.
Contact:
press@hyfe.ai
Comprehensive Chronic Cough Report reveals $15B opportunity. 100M patients, zero FDA-approved drugs, positioning digital cough monitoring as essential pharma infrastructure.
Review including Hyfe research evaluates continuous digital cough monitoring as a practical way to address limitations of patient-reported cough data
Study results demonstrate digital Behavioral Cough Suppression Therapy reduced cough frequency by over 40% in patients with refractory and unexplained chronic cough.
Strategic partnership with KYORIN Pharmaceuticals aims to improve outcomes and expand treatment access to millions impacted by chronic cough globally.